Our network

Moffitt involved in FDA's drug approval for advanced lung cancer | Health

Title (Max 100 Characters)

Moffitt involved in FDA's drug approval for advanced lung cancer
Health, News
Moffitt involved in FDA's drug approval for advanced lung cancer

Tampa, FL - Pfizer Inc. announced Monday that the FDA has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

Dr. Eric Haura and Dr. Alberto Chiappori were involved with the clinical trial held at Moffitt Cancer Center to test XALKORI®.

Lung cancer survivor Doug Trucks, a Walt Disney World employee in Orlando, was on the trial at Moffitt and believes he is still alive today because of this therapy.

Currently, his stage IV non-small cell lung cancer is stable and his symptoms are under control.

"For me, this drug has provided hope. That's the most powerful human emotion I've encountered through my cancer experience," says Trucks, 56, a father of two. "I'm not going to live in fear. I'm not going to be scared of the future."

Worldwide, lung cancer is the leading cause of cancer death in both men and women.10 NSCLC accounts for about 85 percent of lung cancer cases and remains difficult to treat, particularly in the metastatic setting.

Approximately 75 percent of NSCLC patients are diagnosed late with metastatic, or advanced, disease, where the five-year survival rate is only 6 percent.

Health, News

Hillsborough County Deals

Hillsborough County Businesses